Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2529957 | 0.90 | KDM4E (0.59) | KDM4ELMNAHPGDMGLLPOLB | |
| SCHEMBL2533431 | 0.88 | KDM4E (0.55) | KDM4ELMNAHPGDMGLLPOLB | |
| SCHEMBL4879003 | 0.88 | MGLL (0.58) | MGLLPOLBRAB9AALDH1A1NPC1 | |
| SCHEMBL2533853 | 0.87 | KDM4E (0.53) | KDM4ELMNAHPGDMGLLPOLB | |
| SCHEMBL2527618 | 0.87 | KDM4E (0.53) | KDM4ELMNAHPGDMGLLPOLB | |
| SCHEMBL9459601 | 0.86 | MGLL (0.66) | MGLLPOLBRAB9AALDH1A1NPC1 | |
| SCHEMBL655257 | 0.86 | MGLL (0.66) | MGLLPOLBRAB9AALDH1A1NPC1 | |
| SCHEMBL2529867 | 0.85 | KDM4E (0.56) | KDM4ELMNAHPGDMGLLPOLB | |
| SCHEMBL2531101 | 0.85 | KDM4E (0.51) | KDM4ELMNAHPGDMGLLPOLB | |
| SCHEMBL4878443 | 0.84 | MGLL (0.57) | KDM4ELMNAHPGDMGLLPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| WO-2005025554-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005025554-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | KDM4E 3337/4885LMNA 2173/4885HPGD 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.